Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells
- PMID: 12074575
- DOI: 10.1016/S0006-291X(02)00570-3
Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells
Abstract
We have demonstrated previously that IGFBP-5 alone had no effect on cell death but modulated ceramide-induced apoptosis in Hs578T IGF non-responsive cells. To investigate if IGFBP-5 maintains its intrinsic ability to modulate apoptosis in IGF-responsive cells, we used a non-IGF binding mutant of IGFBP-5. In Hs578T cells, non-glycosylated, glycosylated or mutant IGFBP-5 alone each had no effect on cell death, whereas all forms inhibited ceramide-induced apoptosis. In IGF-responsive MCF-7 cells, each wild type form reduced ceramide-induced cell death but mutant IGFBP-5 was without effect. In the presence of mutant IGFBP-5, however, IGF-I no longer conferred survival and in the presence of wild type IGFBP-5, long R3 IGF-I was also unable to confer survival. In summary, all forms of IGFBP-5 modulated ceramide-induced apoptosis in Hs578T cells. In MCF-7 cells, IGF-I-induced survival could be facilitated by IGFBP-5, but also blocked by IGFBP-5 if association with IGFBP-5 was prevented.
Similar articles
-
A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells.Biochem Biophys Res Commun. 2002 Jun 28;294(5):988-94. doi: 10.1016/S0006-291X(02)00569-7. Biochem Biophys Res Commun. 2002. PMID: 12074574
-
Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-I actions.J Cell Physiol. 2005 May;203(2):328-34. doi: 10.1002/jcp.20343. J Cell Physiol. 2005. PMID: 15700281
-
Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells.Br J Cancer. 2002 Jun 17;86(12):1963-9. doi: 10.1038/sj.bjc.6600355. Br J Cancer. 2002. PMID: 12085194 Free PMC article.
-
Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland.Domest Anim Endocrinol. 2005 Aug;29(2):274-82. doi: 10.1016/j.domaniend.2005.02.021. Epub 2005 Apr 7. Domest Anim Endocrinol. 2005. PMID: 15998501 Review.
-
Role of insulin-like growth factor binding protein-3 in breast cancer cell growth.Microsc Res Tech. 2002 Oct 1;59(1):12-22. doi: 10.1002/jemt.10173. Microsc Res Tech. 2002. PMID: 12242693 Review.
Cited by
-
IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiology.J Cell Commun Signal. 2015 Jun;9(2):151-8. doi: 10.1007/s12079-015-0260-3. Epub 2015 Feb 3. J Cell Commun Signal. 2015. PMID: 25645979 Free PMC article.
-
Pitavastatin Regulates Ang II Induced Proliferation and Migration via IGFBP-5 in VSMC.Korean J Physiol Pharmacol. 2015 Nov;19(6):499-506. doi: 10.4196/kjpp.2015.19.6.499. Epub 2015 Oct 16. Korean J Physiol Pharmacol. 2015. PMID: 26557016 Free PMC article.
-
IGF binding proteins (IGFBPs) and regulation of breast cancer biology.J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):455-69. doi: 10.1007/s10911-008-9106-4. Epub 2008 Nov 25. J Mammary Gland Biol Neoplasia. 2008. PMID: 19031049 Review.
-
Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.Crit Rev Oncog. 2015;20(5-6):373-90. doi: 10.1615/CritRevOncog.v20.i5-6.100. Crit Rev Oncog. 2015. PMID: 27279236 Free PMC article. Review.
-
Biological effects and regulation of IGFBP5 in breast cancer.Front Endocrinol (Lausanne). 2022 Aug 25;13:983793. doi: 10.3389/fendo.2022.983793. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36093095 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical